-
Hutchison Medicine's CSF-1R inhibitor HMPL-653 capsule was approved for clinical use in China
Time of Update: 2021-12-07
ArticleMedicine GuanlanAccording to the latest announcement from the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China, Hutchison Medicine’s HMPL-653 capsule has just received an implied clinical trial approval and plans to develop treatments for advanced malignant solid tumors and giant cell tumors of tendon sheaths (TGCT) .
-
The Chinese market has become a growth engine for foreign-funded companies, localized into a key word for multinational pharmaceutical companies
Time of Update: 2021-12-07
In such a wave of innovation, multinational pharmaceutical companies should follow the reform and development trend of China's medical industry, accelerate innovation strategies, and better integrate into the Chinese market .
-
Medical insurance negotiations have ended, and the industry recommends focusing on investment opportunities in this area
Time of Update: 2021-12-07
In the case of more and more standardized clinical drug management, innovative drugs that enter the medical insurance catalog are expected to quickly achieve commercialization, which is especially good for business.
-
AZ over $1 billion injections, Hausen will be approved for Huiyu's new entry
Time of Update: 2021-12-07
Figure 3: Enterprise competitive landscape of 2021H1 Fulvestrant injection Source: Mi Nei. com, China's public medical institutions terminal competition pattern CP Tianqing Pharmaceutical Group submitted 4 types of generic listing applications in 2019, and was approved for the first imitation + first review in August 2020.
-
Jiangsu pharmaceutical company will win the first imitation of 400 million compound painkillers
Time of Update: 2021-12-07
According to data from Meinenet, the total sales of paracetamol and oxycodone tablets in China's public medical institutions and Chinese urban physical pharmacies in 2020 will be approximately 400 million yuan .
-
CGRP migraine competition intensifies Lundbeck Pharma lays off 300 employees
Time of Update: 2021-12-07
CompilationFan DongdongIn February last year, with the approval of the US FDA, Lundbeck Vyepti (a CGRP inhibitor infusion) directly entered the pandemic and migraine market, which is now flooded with injection and oral options from large pharmaceutical companies .
-
AI + drug research and development has become a new trend, multinational pharmaceutical companies accelerate their deployment in China
Time of Update: 2021-12-07
For example, on October 11, during the Shanghai Biomedical Industry Week, AstraZeneca announced that the global R&D China Center was officially completed after the upgrade, and the Shanghai International Life Science Innovation Park and the Medical Artificial Intelligence Innovation Center were officially opened simultaneously .
-
The procurement peak period for vaccine production equipment has passed, where should pharmaceutical machinery companies go?
Time of Update: 2021-12-07
Since 2020, many pharmaceutical machinery companies have benefited from the increase in vaccine-related business and achieved a significant increase in orders for vaccine production equipment, which has contributed to the growth of performance to a certain extent .
-
The medical device sector, the "turning" is coming?
Time of Update: 2021-12-07
According to the news on November 16, the medical device sector rose by 2% as a whole.
It can be seen that domestic medical device products are accelerating the pace of realizing import substitution .
-
The results of medical insurance negotiations may be announced at the end of November.
Time of Update: 2021-12-07
In this year's medical insurance negotiations, Bojian's three rare disease drugs, including noxinagen sodium, dimethyl fumarate, and fampridine, passed the initial formal review of the national medical insurance drug catalog adjustment and appeared at the negotiation site .
-
The innovation of pharmaceutical companies has begun to roll in, and differentiated development will become the key to breaking the game
Time of Update: 2021-12-06
The PD-1 drugs of Hengrui Medicine, BeiGene, and Junshi Bio Qiqi also entered the medical insurance list through negotiations, and the annual treatment cost has been reduced to 50,000 yuan .
-
Pharmaceutical companies are vying to lay out the "hyperglycemic" track, Class 1 new hypoglycemic drugs may welcome a major outbreak
Time of Update: 2021-12-06
According to incomplete statistics, there are currently more than 50 domestically produced Class 1 new hypoglycemic drugs in the clinical application and above stage, 14 of which have entered the phase III clinical and above stage, concentrated in DPP-4, GLP-1, and SGLT-2.
-
EU approves Pfizer's fifth indication for oral JAK inhibitor tofacitinib
Time of Update: 2021-12-06
The results showed that the study reached the primary endpoint: at the 16th week of treatment, compared with the placebo group, the proportion of patients who achieved an ASAS20 response in the Xeljanz treatment group increased significantly (56.
-
The seventh batch of nationally collected varieties has met the conditions (list attached)
Time of Update: 2021-12-06
According to the WeChat public account "Yao Chunqiu", some products of antibacterial drugs currently meet the conditions for entering the seventh batch of national procurement (only based on the competition pattern of enterprises ≥ 3, and other factors such as patents have not been considered for the time being) .
-
Roche terminates development of COVID-19 oral antiviral drug AT-527
Time of Update: 2021-12-06
A few days ago, Roche announced the abandonment of its COVID-19 drug cooperation with Atea Pharmaceuticals .
More than a year ago, Roche and Atea signed a $350 million cooperation agreement for the oral antiviral drug AT-527 .
-
The registration volume of Chinese herbal medicine-related companies has fallen, and the market concentration will further increase
Time of Update: 2021-12-06
Specifically, it can be seen from the development status of Chinese herbal medicine-related companies in the past ten years that the overall number of company registrations is increasing.
-
The cell and gene therapy industry has a high boom, the industry is optimistic about the CGTCDMO track
Time of Update: 2021-12-06
With the continuous growth of the gene cell therapy market, this field is also favored by investors.
Under the influence of policies and capital, the prosperity of the cell and gene therapy industry is expected to continue, and the CGTCDMO track is also favored by the industry .
-
It burned nearly 30 billion in 4 years and has yet to make a profit. Why did BeiGene get IPO approval?
Time of Update: 2021-12-06
The listing also created two new records-BeiGene became the world's first biotech company to be listed on the Nasdaq, China Hong Kong Stock Exchange and the Shanghai Stock Exchange; the proposed fundraising scale for this IPO has reached 20 billion, or will break the record of the highest amount of funds raised by biotech companies since the launch of the Science and Technology Innovation Board .
-
Kangtai Bio's oral five-valent reassortant rotavirus live attenuated vaccine was approved for clinical use
Time of Update: 2021-12-06
On November 17, Kangtai Biologics issued an announcement stating that the oral five-valent reassortant rotavirus live attenuated vaccine (Vero cells) developed by it and its wholly-owned subsidiary Mi
-
China's innovative drug research and development momentum is strong, but the "quality" needs to be improved
Time of Update: 2021-12-06
In addition to PD-1/PD-L1 inhibitors, in recent years, there are not a few pharmaceutical companies that have carried out clinical trials around popular targets of anti-tumor drugs such as VEGF, EGFR, and HER-2.
